This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arena Gets Small Dowry for Obesity Drug

SAN DIEGO ( TheStreet) -- Arena Pharmaceuticals (ARNA - Get Report) is getting just $50 million upfront from the Japanese drug maker Eisai in exchange for U.S. marketing rights to the company's experimental obesity drug lorcaserin.

A $50 million dowry is pretty chincy given the blockbuster sales potential for weight-loss drugs. Eisai and Arena might be engaged but it seems like they've decided to wait before sleeping together.

The U.S. Food and Drug Administration is already reviewing lorcaserin, with an approval decision expected on Oct. 22. At this advanced stage, Eisai would have easily paid well over $100 million in upfront rights for lorcaserin if the company were confident in the drug's approval and commercial potential. Instead, Eisai is holding off, willing to pay Arena big bucks -- upwards of $1 billion or more -- only if lorcaserin is approved and generates top-tier sales, according to terms of the agreement announced Thursday.

Still, Arena deserves kudos for being the first of the obesity drug players to land a marketing partner. Investors have been watching closely to see if any the large drug companies would latch onto one of these weight-loss drugs now making their way through the U.S. Food and Drug Administration review process. Arena won this stage of the competition, while rivals Vivus (VVUS - Get Report) and Orexigen Therapeutics (OREX - Get Report) are still single.

The chief concern with lorcaserin is that patients treated with the drug in two pivotal phase III studies didn't lose much weight -- a little more than 3% on a placebo adjusted basis. The biggest positive in lorcaserin's corner is the drug's safety and tolerability, which appear better than its rivals.

An FDA advisory panel will review lorcaserin on Sept. 16.

Investors are reacting to Arena's partnering announcement Thursday with relatively cool detachment, likely due to Eisai's small upfront payment. Arena shares are up 62 cents, or 20%, to $3.69 in pre-market trading. The stock closed Wednesday at $3.07.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.58 0.00%
OREX $0.41 0.00%
VVUS $1.37 0.00%
AAPL $93.24 0.00%
FB $117.81 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs